For most of the twentieth century, inflammation was thought to subside passively — once the offending stimulus was removed, inflammatory mediators simply diluted away. That assumption collapsed in 2000 when Charles Serhan’s laboratory at Harvard discovered that the resolution of inflammation is an active, tightly programmed biochemical process orchestrated by a family of lipid mediators biosynthesized from EPA and DHA. These molecules — resolvins, maresins, and protectins — don’t block inflammation. They end it, and then they tell tissues to heal.
What Are Resolvins and Specialized Pro-Resolving Mediators?
Specialized pro-resolving mediators (SPMs) are a class of endogenous lipid mediators biosynthesized from omega-3 polyunsaturated fatty acids during the resolution phase of acute inflammation. The family includes resolvins (derived from EPA and DHA), protectins (from DHA), and maresins (from DHA, produced primarily by macrophages). Each is generated through sequential enzymatic action of lipoxygenases and cyclooxygenases on essential fatty acid substrates.[1]
The discovery emerged from lipidomic analysis of resolving inflammatory exudates, where Serhan and colleagues identified previously unknown bioactive lipids appearing precisely as neutrophil infiltration was being terminated and macrophage clearance of debris was beginning. Unlike classical anti-inflammatory drugs that suppress prostaglandin or leukotriene production, SPMs are agonists — they actively engage G-protein-coupled receptors to drive resolution programs.[1]
How Resolvins Work
Class Switching of Lipid Mediators: During acute inflammation, arachidonic acid initially generates pro-inflammatory prostaglandins and leukotrienes. As inflammation peaks, prostaglandin E2 and D2 paradoxically induce a transcriptional switch in neutrophils and macrophages — shifting lipoxygenase expression to favor production of lipoxins from arachidonic acid and resolvins from EPA and DHA. This class switching is the biochemical commitment to resolution.[2]
Receptor-Mediated Signaling: Resolvin E1 binds the ChemR23 receptor and antagonizes the BLT1 leukotriene B4 receptor on neutrophils, simultaneously promoting resolution signals and blocking pro-inflammatory recruitment. Resolvin D1 acts through ALX/FPR2 and GPR32 receptors. These are high-affinity interactions — RvE1 is bioactive in the nanomolar to picomolar range.[2]
Neutrophil Cessation and Efferocytosis: SPMs halt further neutrophil infiltration without immunosuppression and stimulate macrophage efferocytosis — the non-phlogistic clearance of apoptotic neutrophils. This clearance is essential; failure of efferocytosis underlies chronic inflammation in atherosclerosis, COPD, and autoimmune disease.[3]
Macrophage Reprogramming: Maresin 1 (Macrophage Mediator in Resolving Inflammation) shifts macrophages from the M1 pro-inflammatory phenotype toward an M2 reparative phenotype, promoting tissue regeneration and reducing fibrosis. Protectin D1 reduces neutrophil transmigration and exerts neuroprotective effects in retinal and brain tissue.[3]
Clinical Evidence
Cardiovascular Disease: In the GISSI-Prevenzione trial, supplementation with 1 g/day of EPA+DHA reduced sudden cardiac death by 45% in post-myocardial infarction patients over 3.5 years — an effect that long predated mechanistic understanding but is now partly attributed to SPM biosynthesis from omega-3 substrate.[4] Subsequent work has shown that atherosclerotic plaques from patients with vulnerable lesions exhibit reduced SPM-to-leukotriene ratios, suggesting that resolution failure, not merely inflammation initiation, drives plaque instability.[3]
Triglyceride Lowering and Beyond: The REDUCE-IT trial demonstrated that high-dose icosapent ethyl (4 g/day of purified EPA) reduced major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides. The magnitude of benefit exceeded what would be expected from triglyceride reduction alone, leading investigators to invoke EPA’s role as substrate for E-series resolvins and its membrane stabilization effects.[5]
Periodontal and Mucosal Inflammation: Resolvin E1 has been studied extensively in periodontitis models, where topical application restored periodontal bone in animal models of disease. Human studies of omega-3 supplementation in periodontitis have shown reductions in pocket depth and inflammatory cytokines consistent with enhanced resolution biology.[1]
Neuroinflammation and Pain: SPMs cross the blood-brain barrier and act on neural tissue. Resolvin D1 and D2 reduce inflammatory pain in preclinical models at doses orders of magnitude below those required for NSAIDs, without affecting normal nociception. Reduced SPM levels have been documented in patients with Alzheimer’s disease cerebrospinal fluid, raising the possibility that resolution failure contributes to chronic neuroinflammation.[3]
Safety Profile
SPMs themselves are endogenous molecules with no known toxicity at physiologic concentrations. The clinical safety question centers on their precursors — EPA and DHA — which have been extensively studied. Standard fish oil supplementation at 1–4 g/day is well tolerated, with gastrointestinal complaints (fishy eructation, mild loose stools) being the most common adverse effects. Bleeding risk at typical doses is minimal; even at the 4 g/day dose used in REDUCE-IT, serious bleeding events were only modestly increased and were not offset by reduction in cardiovascular events.[5]
A relevant consideration is that SPM biosynthesis requires not only sufficient EPA/DHA substrate but also functional lipoxygenase enzymes. Aspirin acetylates COX-2, redirecting it to produce aspirin-triggered epimers of resolvins (17R-resolvin D series) that are more resistant to enzymatic degradation — a mechanism that may underlie aspirin’s benefits beyond platelet inhibition.[2]
Resolvins vs. NSAIDs and Conventional Anti-Inflammatories
Mechanistic Inversion: NSAIDs and corticosteroids work by inhibition — blocking COX enzymes or suppressing transcriptional programs that produce inflammatory mediators. This approach reduces inflammatory output but does not actively drive resolution. SPMs invert this logic: rather than turning off the on-switch, they engage the off-switch.
Tissue Healing: Conventional anti-inflammatories often impair tissue repair. NSAIDs delay fracture healing and impair tendon-to-bone integration. Glucocorticoids suppress fibroblast activity and wound closure. SPMs, by contrast, actively promote macrophage-mediated tissue regeneration and have been shown to enhance, not impair, healing in preclinical models.[3]
Immunosuppression Risk: Resolution is not immunosuppression. SPMs do not impair the initial response to pathogens; in animal models of bacterial infection, SPMs actually enhance host defense by improving bacterial clearance while limiting collateral tissue damage. This is fundamentally different from corticosteroid-induced immunosuppression.[1]
Substrate Strategy: The clinical translation of resolution biology has so far relied less on administering SPMs directly (most are unstable and have short half-lives) than on providing abundant EPA and DHA substrate so that endogenous biosynthesis can proceed when resolution programs are triggered. This is the rationale for high-dose omega-3 trials in cardiovascular and inflammatory disease.[4][5]
Stable synthetic SPM analogs and receptor agonists are in development and represent the next phase of translation — therapeutics designed not to block inflammation, but to end it on time.
References
- Serhan CN. “Pro-resolving lipid mediators are leads for resolution physiology.” Nature. 2014;510(7503):92-101.
- Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. “Lipid mediator class switching during acute inflammation: signals in resolution.” Nature Immunology. 2001;2(7):612-619.
- Serhan CN, Chiang N, Dalli J, Levy BD. “Lipid mediators in the resolution of inflammation.” Cold Spring Harbor Perspectives in Biology. 2015;7(2):a016311.
- GISSI-Prevenzione Investigators. “Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial.” Lancet. 1999;354(9177):447-455.
- Bhatt DL, Steg PG, Miller M, et al. “Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.” New England Journal of Medicine. 2019;380(1):11-22.
